A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquaamous NSCLC

Mark James McKeage, Dusan Kotasek, Ben Markman, Manuel Hidalgo, Michael Millward, Michael B. Jameson, Dean Laurence Harris, Robert J. Stagg, Jakob Dupont, Brett Gordon Maxwell Hughes

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

2 Citations (Web of Science)
Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Volume32
Issue number15
DOIs
Publication statusPublished - 20 May 2014
Externally publishedYes
Event50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 30 May 20143 Jun 2014

Cite this